RxSight (NASDAQ:RXST) COO Ilya Goldshleger Sells 2,041 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) COO Ilya Goldshleger sold 2,041 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $6.96, for a total transaction of $14,205.36. Following the sale, the chief operating officer owned 81,509 shares of the company’s stock, valued at approximately $567,302.64. The trade was a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

RxSight Stock Performance

Shares of RxSight stock traded up $0.04 during trading hours on Wednesday, reaching $7.03. The company’s stock had a trading volume of 778,865 shares, compared to its average volume of 898,096. RxSight, Inc. has a one year low of $4.48 and a one year high of $13.22. The company’s 50 day simple moving average is $5.95 and its 200 day simple moving average is $6.35. The stock has a market cap of $292.40 million, a P/E ratio of -6.22 and a beta of 1.16.

RxSight (NASDAQ:RXST) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.04. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. The firm had revenue of $33.74 million for the quarter, compared to analyst estimates of $32.55 million. On average, sell-side analysts predict that RxSight, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Raymond James Financial Inc. bought a new stake in shares of RxSight during the second quarter valued at about $28,000. Summit Securities Group LLC bought a new position in RxSight in the 1st quarter valued at about $30,000. Larson Financial Group LLC grew its position in RxSight by 110.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after buying an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in RxSight by 440.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company’s stock valued at $39,000 after buying an additional 3,063 shares during the period. Finally, CWM LLC increased its stake in RxSight by 211.1% during the 4th quarter. CWM LLC now owns 3,826 shares of the company’s stock valued at $40,000 after buying an additional 2,596 shares during the period. 78.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RXST has been the subject of a number of recent research reports. Wells Fargo & Company lowered their price objective on RxSight from $11.00 to $9.00 and set an “equal weight” rating for the company in a research note on Thursday, May 7th. Jefferies Financial Group set a $6.50 price target on shares of RxSight in a report on Tuesday, July 7th. Wall Street Zen lowered shares of RxSight from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings cut shares of RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Finally, Stifel Nicolaus cut their price objective on shares of RxSight from $8.00 to $7.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Two investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $8.37.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.